Senate Bill 1084 would change the current method used by insurers for prior authorization, step therapy, and fail-first protocols. The Associated Industries of Florida opposes this bill because it would negatively impact evidence-based standards of care currently in place and force insurers and consumers to purchase more expensive drugs when equally effective and lower-cost alternatives exist. AIF supports continued flexibility for health plans to provide high-quality, high-value, and affordable care through innovative plan designs. Senate Bill 1084 has been referred to the Senate Committee on Health Policy and Senate Appropriations.
Senate Bill 1084 would change the current method used by insurers for prior authorization, step therapy, and fail-first protocols. The Associated Industries of Florida opposes this bill because it would negatively impact evidence-based standards of care currently in place and force insurers and consumers to purchase more expensive drugs when equally effective and lower-cost alternatives exist. AIF supports continued flexibility for health plans to provide high-quality, high-value, and affordable care through innovative plan designs. Senate Bill 1084 has been referred to the Senate Committee on Health Policy and Senate Appropriations.
Senate Bill 1084 would change the current method used by insurers for prior authorization, step therapy, and fail-first protocols. The Associated Industries of Florida opposes this bill because it would negatively impact evidence-based standards of care currently in place and force insurers and consumers to purchase more expensive drugs when equally effective and lower-cost alternatives exist. AIF supports continued flexibility for health plans to provide high-quality, high-value, and affordable care through innovative plan designs. Senate Bill 1084 has been referred to the Senate Committee on Health Policy and Senate Appropriations.
Senate Bill 1084 would change the current method used by insurers for prior authorization, step therapy, and fail-first protocols. The Associated Industries of Florida opposes this bill because it would negatively impact evidence-based standards of care currently in place and force insurers and consumers to purchase more expensive drugs when equally effective and lower-cost alternatives exist. AIF supports continued flexibility for health plans to provide high-quality, high-value, and affordable care through innovative plan designs. Senate Bill 1084 has been referred to the Senate Committee on Health Policy and Senate Appropriations.
AIF Statement in Opposition of Step Therapy Legislation
Tallahassee, Fla. The Associated Industries of Florida (AIF) today released the following statement attributed to its General Counsel Tamela Perdue in opposition to Senate Bill 1084, which would change the current, effective method of prior authorization, step therapy and fail-first protocols. AIF today opposed SB 1084 because it would negatively impact the standards of care that are currently in place and based on real-time protocols that are centered on evidence-based research. By changing the current, effective methods which are used for the safest, most cost-effective drug and permit processing it would force insurers and consumers to purchase the most expensive drugs and treatments even when equally effective drugs and treatments are available at much lower costs. AIF supports continued flexibility for health plans to ensure consumers receive high quality, high value and affordable care, through continued use of innovative plan designs to achieve this balance. AIF opposes this legislation because we believe it would only increase costs, regulation and bureaucratic red tape. Senate Bill 1084 has also been referred to the Senate Committee on Health Policy and Senate Appropriations. For more information on AIF, please visit AIF.com and follow @VoiceofFLBiz. ###